Adoptive T cell therapies can be used, alone or in combination with checkpoint inhibitors, to selectively enhance T cell responses towards MHC-restricted tumor-associated antigens (TAA) and/or tumor-specific antigens (neoantigens) presented on tumor cells (Cable et al., 2021). This evidence concerns the gene HLA-C and neoplasm.